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Background: The purpose of this open-label study was to investigate the effect of a 
curcumin-phospholipid (lecithin, Meriva®) formulation (Norflo® tablet) on visual acuity and 
retinal thickness in patients with acute or chronic central serous chorioretinopathy.
Methods: Visual acuity was assessed by ophthalmologic evaluation, and optical coherence 
tomography was used to measure retinal thickness. Norflo tablets were administered twice a 
day to patients affected by central serous chorioretinopathy. The study included 18 eyes from 
12 patients who completed a 6-month follow-up period. Visual acuity before and after Norflo 
treatment was the primary endpoint. The secondary endpoints were neuroretinal or pigment 
epithelial detachment, as measured by optical coherence tomography.
Results: After 6 months of therapy, 0% of eyes showed reduction in visual acuity, 39% showed 
stabilization, and 61% showed improvement. The improvement was statistically significant 
(P = 0.08). After 6 months of therapy, 78% of eyes showed reduction of neuroretinal or retinal 
pigment epithelium detachment, 11% showed stabilization, and 11% showed an increase.
Conclusion: Our results, albeit preliminary, show that curcumin administered as Norflo tablets 
is efficacious for the management of central serous chorioretinopathy, a relapsing eye disease, 
and suggest that bioavailable curcumin is worth considering as a therapeutic agent for the 
management of inflammatory and degenerative eye conditions, including those that activate 
the retinal microglia.
Keywords: curcumin, central serous chorioretinopathy, retinal pigment epithelium detachment, 
Norflo®, Meriva®
Introduction
Central serous chorioretinopathy, first described by Von Graefe in 1866 and also 
known as recurrent central retinitis,1 is a well characterized disorder leading to serous 
neurosensory elevation of the retina. The acute form of the disease is associated with 
focal leakage at the level of the retinal pigment epithelium and hyperpermeability of 
the choroid, and can be diagnosed on fluorescein and indocyanine green angiography.2 
The disorder is self-limiting in the majority of patients, who usually retain excellent 
vision. However, cases that do not resolve spontaneously can develop pigment 
epithelium and photoreceptor damage, resulting in permanent visual impairment. The 
pathophysiology of central serous chorioretinopathy remains poorly understood, but 
the cascade of events leading to neurosensory detachment includes, or might even be 
triggered by, changes in choroid permeability.
Curcumin has antioxidant and anti-inflammatory activity, and has shown efficacy 
in animal models of acute and chronic inflammation of relevance to eye disease. 
Dovepress




open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OPTH.S31859Clinical Ophthalmology 2012:6
Using cultured corneal cells from the transgenic mouse, it 
was shown that curcumin targets fibroblast growth factor-2 
and inhibits expression of gelatinase B, critically affecting 
angiogenesis.3 Furthermore, in an animal model of dry eye, 
curcumin showed anti-inflammatory effects in cultured 
corneal epithelial cells exposed to hyperosmotic conditions.4 
Finally, curcumin has been shown to reduce oxidative stress, 
the main cause of cataract progression,3,5–15 in a murine model 
of chemically induced hyperglycemia,16 by inhibiting cell 
proliferation and production of cytokines, which are the 
main triggers of the inflammatory response.15 Curcumin 
is a pleiotropic agent, for which over 100 different targets 
have been identified. Within an anti-inflammatory context, 
upregulation of peroxisome proliferator-activated receptor 
(PPAR)-γ, a ligand-inducible transcription factor, plays a key 
role, because activation of PPAR-γ controls responses of the 
microglia and limits inflammation.17–21 Taken together, these 
observations provided a rationale for studying the effect of 
curcumin in patients with central serous chorioretinopathy. 
This condition is triggered and sustained by inflammation, 
and a previous study had identified ibuprofen and aspirin 
as promising agents for the treatment of central serous 
chorioretinopathy,17,18 in which elevated levels of plasmino-
gen activator inhibitor occur.22,23 Curcumin has poor systemic 
availability, but formulation with phospholipids from lecithin 
(Meriva®) dramatically increases its oral absorption,24–28 so 
avoids the use of megadoses that would jeopardize patient 
compliance.
Materials and methods
A total of 18 eyes from 12 patients (11 men, one woman) 
referred to our tertiary retinal center in Milan for treatment 
of central serous chorioretinopathy were enrolled in the 
study. The age of the patients ranged from 29 to 68 years. 
All patients provided their written informed consent 
before entering the study, in accordance with the tenets of 
the Declaration of Helsinki. Diagnosis of central serous 
chorioretinopathy was based on optical coherence tomography 
(OCT) and angiography with fluorescein and indocyanine 
green. Ophthalmological examination also included slit-
lamp examination, Early Treatment Diabetic Retinopathy 
Study best-corrected visual acuity measurement, intraocular 
pressure measurement, and fundus examination using a 
Volk + 90 D lens. Enhanced-depth OCT is a new imaging 
modality (Spectralis, Heidelberg Engineering, Heidelberg, 
Germany) that allows reproducible measurement of choroidal 
thickness and may be useful as an aid for differentiating central 
serous chorioretinopathy from other retinal pathology, eg, 
age-related macular degeneration. The most recent version of 
the Spectralis software incorporates enhanced-depth imaging 
into the scanning protocol, but was not available for this study. 
Follow-up is ongoing, but all patients successfully completed 
at least 6 months of treatment. All patients underwent a full 
ophthalmological examination at days 0, 30, 90, and 180. 
The results was compared before and after 180 days of 
treatment. Ad hoc medical record reporting was performed 
at each follow-up visit. A black and white Amsler grid was 
recorded at each visit.
All patients received two Norflo® tablets (Eye Pharma Co, 
Italy) per day, corresponding to 1.2 g of lecithinized curcumin 
(Meriva®, Indena, Milano, Italy), during the study period. 
This therapy was administered to patients who had frequent 
relapses in the last one year of follow-up, and was started 
at the time of first diagnosis in naïve patients. We also 
investigated the percentage of satisfaction and tolerance 
to additional therapy by means of a detailed questionnaire 
(included on the clinical record sheet) developed to assess 
patient tolerance and compliance with Norflo treatment. 
Visual acuity and neuroretinal or pigment epithelial detach-
ment were assessed before and after treatment.
The Student’s t-test and Wilcoxon Signed-Rank test were 
used to assess the statistical significance of changes in best-
corrected visual acuity and retinal thickness.
Results
At baseline, mean best-corrected visual acuity was 0.63 ± 0.2 
(logMAR 0.2 ± 0.7). After 6 months of treatment, best-
corrected visual acuity improved to 0.8 ± 0.2 (logMAR 
0.1 ± 0.7); 0% of eyes showed reduction in visual acuity, 39% 
showed stability, and 61% showed improvement (Figure 1). 
This improvement was statistically significant (P = 0.08). 
Average neuroretinal/retinal pigment epithelium detachment 
at baseline was 317.8 µ ± 80.2 µ. Seventy-eight percent of 
eyes showed a reduction of neuroretinal/retinal pigment epi-
thelium detachment, 11% showed stability, and 11% showed 
an increase (Figures 2 and 3). Mean neuroretinal/retinal 
pigment epithelium detachment decreased to 277 µ ± 49.5 µ 
in the treatment group, and the difference was statistically 
significant after 6 months (P = 0.96). No statistically 
significant differences were observed for near best-corrected 
visual acuity, and all patients reported improvement in the 
appearance of the Amsler grid as distortions, blurring, dis-
coloration, or other change. No systemic adverse effects were 
observed. The significance testing results simply reflect an 
insufficient sample size and the distribution of data obtained 
for visual acuity and OCT retinal thickness.






























Figure 2 retinal thickness after 6 months of treatment with the curcumin-lecithin formulation. 
Abbreviation: OCT, optical coherence tomography.



















Anti-inflammatory agents, including ibuprofen and 
aspirin, have been used in the treatment of central serous 
chorioretinopathy,23,29 providing a rationale for the use 
of curcumin in this condition. The anti-inflammatory 
mechanism of curcumin is pleiotropic, and involves 
inhibition of proinflammatory transcription factors and 
enzymes at both the functional and genomic levels. Curcumin 
is also an activator of PPAR-γ,30 a transcription factor, the 
stimulation and upregulation of which is associated with 
significant anti-inflammatory activity.7 The main immune 
cells involved in ocular inflammation are the glia and 
microglia, in which the function of PPAR-γ, a sensor of 
metabolism, is critically involved. Therefore, modulation of 
PPAR-γ has considerable potential in many ocular diseases, 
including vitreoretinopathy, diabetic retinopathy, glaucoma, 
and age-related macular degeneration.17
Despite these interesting clues, the clinical activity 
of curcumin does not correspond to its pharmacological 
potential, with the dismally low oral bioavailability of the 
natural product hampering translation of the many promising 
results observed in in vitro and animal studies into the clinical 
setting. To overcome the bioavailability problem, a lecithin 
formulation of curcumin (Meriva®) has been developed, 
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and incorporation into a phospholipid matrix leads to an 
almost 30-fold increase in absorption, effectively overcoming 
the megadose issue reported in the literature to have plagued 
this compound.25–28,31,32
Encouraged by the activity of curcumin in inflammatory 
eye diseases,17–19,26,33–41 as well as the improvement in 
absorption associated with Meriva, we investigated the 
potential of curcumin formulated as Norflo tablets in the 
management of central serous chorioretinopathy, a chronic 
relapsing eye disease. Central serous chorioretinopathy 
is associated with various conditions characterized by 
exposure to increased levels of endogenous or exogenous 
glucocorticoids, as shown by its association with Cushing’s 
syndrome. It is also prevalent in patients with type A 
behavior, and stressful events and pregnancy might represent 
other risk factors for the disease, all conditions being 
characterized by endogenous hypercortisolism. In addition, 
many cases of central serous chorioretinopathy have been 
described during or following treatment with glucocorticoids 
administered by any route for various systemic or ocular 
conditions.42,43 Twelve patients were enrolled in this open-
label study, with examination of 18 eyes. All patients 
completed at least 6 months of follow-up with no dropouts, 
indicating the excellent tolerability of the treatment and 
good quality of life for patients, with follow-up visits 
consistently showing overall patient well being. Significant 
reversal of decreased visual acuity and improvement in the 
histological status of the disease were observed in all patients. 
In view of the small number of patients in this study, its 
short follow-up duration, and inclusion of different types of 
central serous chorioretinopathy, it is theoretically possible 
that the observed improvement was spontaneous or that 
resolution was simply coincident with the study treatment. 
Nevertheless, the reduction in retinal pigment epithelium and 
neurosensory detachment, as well as improvement in visual 
acuity, but not necessarily disease resolution, suggests that 
Meriva may be efficacious in the treatment of central serous 
chorioretinopathy.
In general, central serous chorioretinopathy has an 
unpredictable prognosis, so it is difficult to make specific 
treatment recommendations. However, treatment should be 
considered after 3 months without spontaneous resolution 
of acute or chronic central serous chorioretinopathy.43 
Resolution of detachment can usually be achieved in acute 
central serous chorioretinopathy by focal photocoagulation 
of leaking retinal pigment epithelium lesions, and in chronic 
central serous chorioretinopathy by photodynamic therapy, 
but the effect of these therapies on long-term visual outcome 
is not adequately documented. Reattachment within 4 months 
of onset is considered an appropriate therapeutic aim 
because prolonged detachment is associated with atrophy of 
photoreceptors. These considerations suggest that treatment 
with lecithinized curcumin could be useful both as prompt 
therapy aimed at retinal reattachment and as adjunctive 
therapy to reduce the number of relapses in the advanced 
stages of the disease.
Conclusion
Because of its anti-inflammatory profile and angiogenesis-
modulating properties, curcumin has great potential in 
the treatment of retinal inflammatory conditions and 
retinal neovascular proliferative diseases sustained by 










Figure 3 retinal thickness after 6 months of treatment with the curcumin-lecithin 
formulation in three different cases. (A) Case 1, reduction of a subfoveal neuroretinal 
detachment.  (B)  Case  2,  reduction  of  a  juxtafoveal  retinal  pigment  epithelium 
detachment and extrafoveal neuroretinal detachment. (C) Case 3, reduction of a 
juxtafoveal retinal pigment epithelium and extrafoveal neuroretinal detachment.





Formulation with lecithin has been shown to be benefi-
cial for the absorption of curcumin, and we have shown 
that lecithinized curcumin (Meriva), administered in the 
form of two tablets of Norflo per day, could provide ben-
eficial effects in patients suffering from central serous 
chorioretinopathy, reversing their decline in visual acuity 
and improving the histological status of their disease. 
Despite the limitations of this study in terms of number 
of patients, duration of follow-up, and heterogeneity of 
central serous chorioretinopathy, the reduction in retinal 
pigment epithelium and neurosensory detachment, as well 
as improvement in visual acuity, is very promising. Our 
results suggest that appropriately formulated curcumin 
has great potential in the management of central serous 
chorioretinopathy, and provides a rationale for initiation of 
larger placebo-controlled studies that might also consider 
the combination of curcumin with other therapeutic options 
to treat this disease, eg, low-fluence photodynamic therapy 
and intravitreal therapy.
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